Evidence map›Paper›PMID 35106317›Full record

ArticleOpen forum infectious diseases2022

Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement.

Michael J Peluso, J Daniel Kelly, Scott Lu, Sarah A Goldberg, Michelle C Davidson, Sujata Mathur, Matthew S Durstenfeld, Matthew A Spinelli, Rebecca Hoh, Viva Tai and 37 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 5 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 5 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Global prevalence of post-COVID-19 condition: a systematic review and meta-analysis of prospective evidence.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2025
    Pooled it
  4. Pooled it
  5. Long-Term Consequences of COVID-19 at 6 Months and Above: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022
    Pooled it
  6. Persistent cytolytic CD8Cell reports. Medicine · 2026
    Article
  7. Prevalence of Long COVID inJournal of clinical tuberculosis and other mycobacterial diseases · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Neuroimmune pathophysiology of long COVID.Psychiatry and clinical neurosciences · 2025
    Review
  17. Article
  18. Article
  19. Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

47 authors at 2 institutions in 1 country.

Michael J PelusoDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-0585-6230
J Daniel KellyDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Scott LuDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Sarah A GoldbergDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Michelle C DavidsonDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Sujata MathurDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Matthew S DurstenfeldDivision of Cardiology, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
Matthew A SpinelliDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
Rebecca HohDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
Viva TaiDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
Emily A FehrmanDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
Leonel TorresDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
Yanel HernandezDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
Meghann C WilliamsDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
Mireya I ArreguinDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
Lynn H NgoDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
Monika DeswalDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
Sadie E MunterDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
Enrique O MartinezDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
Khamal A AnglinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Mariela D RomeroDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Jacqueline TavsDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Paulina R RugartDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Jessica Y ChenDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Hannah M SansDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Victoria W MurrayDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
Payton K EllisDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Kevin C DonohueDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Jonathan A MassachiDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Jacob O WeissDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Irum MehdiDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Jesus Pineda-RamirezDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Alex F TangDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Megan A WengerDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Melissa T AssenzioDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Yan YuanDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Melissa R KroneDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Rachel L RutishauserDivision of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA.
Isabel Rodriguez-BarraquerDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
Bryan GreenhouseDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
John A SaucedaCenter for AIDS Prevention Studies, University of California, San Francisco, San Francisco, California, USA.
Monica GandhiDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-7025-1994
Aaron Wolfe SchefflerDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Priscilla Y HsueDivision of Cardiology, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
Timothy J HenrichDivision of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA.
Steven G DeeksDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
Jeffrey N MartinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
University of California, San Francisco · USSan Francisco General Hospital · US

Funding

MOLECULAR AND CELLULAR BASIS OF CARDIOVASCULAR DISEASET32HL007731 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brian L Black · 1992 to 2026
$12.4M
Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
Targeting Non Viral Markers of HIV PersistenceR01AI141003 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HENRICH, TIMOTHY JENSEN · 2018 to 2022
$4.9M
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinicR01AI158013 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA, SPINELLI, MATTHEW A. · 2020 to 2023
$3.1M
UCSF Career Development Program in Cardiopulmonary, Hematologic, and Immunologic Comorbidities of HIV (CHIC)K12HL143961 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSUE, PRISCILLA Y., HUANG, LAURENCE · 2018 to 2022
$1.8M
Mentoring translational scientists in international infectious disease researchK24AI144048 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bryan R Greenhouse · 2019 to 2026
$1.6M
Characterizing the virologic and immunologic signatures of HIV exceptional controlK23AI157875 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PELUSO, MICHAEL JOSEPH · 2021 to 2025
$927k
Understanding the epidemiology and natural history of unrecognized Ebola virus infectionK23AI146268 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KELLY, JOHN DANIEL · 2019 to 2022
$748k
Translational Studies of Plasmodium Falciparum Infection DynamicsK23AI076614 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GREENHOUSE, BRYAN R · 2008 to 2012
$609k
Evaluation of the Impact of HIV Status on the Immune Response to mRNA COVID-19 VaccinesR21AI167648 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA, SPINELLI, MATTHEW A. · 2022 to 2023
$444k
NHLBI NIH HHS K12 HL143961NHLBI NIH HHS T32 HL007731NIAID NIH HHS K23 AI076614NIAID NIH HHS K23 AI146268NIAID NIH HHS K23 AI157875NIAID NIH HHS K24 AI144048NIAID NIH HHS L30 AI126521NIAID NIH HHS L30 AI147159NIAID NIH HHS R01 AI141003NIAID NIH HHS R01 AI158013NIAID NIH HHS R21 AI167648NIAID NIH HHS T32 AI060530
6 · The paper itself

Abstract

backgroundThere is mounting evidence for the presence of postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC), but there is limited information on the spectrum, magnitude, duration, and patterns of these sequelae as well as their influence on quality of life.

methodsWe assembled a cohort of adults with a documented history of SARS-CoV-2 RNA positivity at ≥2 weeks past onset of coronavirus disease 2019 (COVID-19) symptoms or, if asymptomatic, first positive test. At 4-month intervals, we queried physical and mental health symptoms and quality of life.

resultsOf the first 179 participants enrolled, 10 were asymptomatic during the acute phase of SARS-CoV-2 infection, 125 were symptomatic but not hospitalized, and 44 were symptomatic and hospitalized. During the postacute phase, fatigue, shortness of breath, concentration problems, headaches, trouble sleeping, and anosmia/dysgeusia were most common through 8 months of observation. Symptoms were typically at least somewhat bothersome and sometimes exhibited a waxing-and-waning course. Some participants experienced symptoms of depression, anxiety, and post-traumatic stress, as well as difficulties with performance of usual activities. The median visual analogue scale rating of general health was lower at 4 and 8 months compared with pre-COVID-19. Two clusters of symptom domains were identified.

conclusionsMany participants report bothersome symptoms following onset of COVID-19 with variable patterns of persistence and impact on quality of life. The substantial variability suggests the existence of multiple subphenotypes of PASC. A rigorous approach to the prospective measurement of symptoms and functional manifestations sets the stage for the next phase of research focusing on the pathophysiologic causes of the various subgroups of PASC.

Indexed as

COVID-19long COVIDpost-acute sequelae of SARS-CoV-2 (PASC)quality of lifeSARS-CoV-2

Identifiers

PMID35106317
PMCPMC8755302
OpenAlexW4200212226

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.